Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1991 Nov;50(Suppl 4):877–886. doi: 10.1136/ard.50.suppl_4.877

Treatment of systemic sclerosis.

T A Medsger Jr 1
PMCID: PMC1033324  PMID: 1750801

Abstract

Proper classification of patients into diffuse cutaneous and limited cutaneous subsets and the anticipation of complications are the keys to the management of subjects with systemic sclerosis (scleroderma). Patients with early diffuse disease and rapidly progressive skin thickening are at highest risk of developing serious disease of the internal organs (intestine, lung, heart, kidney) and should be considered for disease modifying treatment. The targets of the disease and sites of possible intervention are vascular endothelium (vasoprotective agents), mononuclear cell subsets (immunosuppressive agents), and fibroblasts (colchicine, D-penicillamine). A number of new agents with sound scientific rationale are currently undergoing therapeutic trials. Much can be done to improve the lifestyle of those with scleroderma. The most dramatic recent development is the ability to reverse kidney disease by the prompt use of angiotensin converting enzyme inhibitors and modern methods of renal dialysis and transplantation. Scleroderma is not a hopeless disease.

Full text

PDF
877

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alarcon-Segovia D., Ramos-Niembro F., Ibanez de Kasep G., Alcocer J., Tamayo R. P. Long-term evaluation of colchicine in the treatment of scleroderma. J Rheumatol. 1979 Nov-Dec;6(6):705–712. [PubMed] [Google Scholar]
  2. Baker G. L., Kahl L. E., Zee B. C., Stolzer B. L., Agarwal A. K., Medsger T. A., Jr Malignancy following treatment of rheumatoid arthritis with cyclophosphamide. Long-term case-control follow-up study. Am J Med. 1987 Jul;83(1):1–9. doi: 10.1016/0002-9343(87)90490-6. [DOI] [PubMed] [Google Scholar]
  3. Balaban E. P., Sheehan R. G., Lipsky P. E., Frenkel E. P. Treatment of cutaneous sclerosis and aplastic anemia with antithymocyte globulin. Ann Intern Med. 1987 Jan;106(1):56–58. doi: 10.7326/0003-4819-106-1-56. [DOI] [PubMed] [Google Scholar]
  4. Beckett V. L., Conn D. L., Fuster V., Osmundson P. J., Strong C. G., Chao E. Y., Chesebro J. H., O'Fallon W. M. Trial of platelet-inhibiting drug in scleroderma. Double-blind study with dipyridamole and aspirin. Arthritis Rheum. 1984 Oct;27(10):1137–1143. doi: 10.1002/art.1780271009. [DOI] [PubMed] [Google Scholar]
  5. Berger R. G., Featherstone G. L., Raasch R. H., McCartney W. H., Hadler N. M. Treatment of calcinosis universalis with low-dose warfarin. Am J Med. 1987 Jul;83(1):72–76. doi: 10.1016/0002-9343(87)90499-2. [DOI] [PubMed] [Google Scholar]
  6. Binnick S. A., Shore S. S., Corman A., Fleischmajer R. Failure of dimethyl sulfoxide in the treatment of scleroderma. Arch Dermatol. 1977 Oct;113(10):1398–1402. [PubMed] [Google Scholar]
  7. Black C. M., McWhirter A., Harrison N. K., Kirk J. M., Laurent G. J. Serum type III procollagen peptide concentrations in systemic sclerosis and Raynaud's phenomenon: relationship to disease activity and duration. Br J Rheumatol. 1989 Apr;28(2):98–103. doi: 10.1093/rheumatology/28.2.98. [DOI] [PubMed] [Google Scholar]
  8. Blom-Bülow B., Oberg K., Wollheim F. A., Persson B., Jonson B., Malmberg P., Boström H., Herbai G. Cyclofenil versus placebo in progressive systemic sclerosis. A one-year double-blind crossover study of 27 patients. Acta Med Scand. 1981;210(5):419–428. [PubMed] [Google Scholar]
  9. Blunt R. J., Porter J. M. Raynaud syndrome. Semin Arthritis Rheum. 1981 May;10(4):282–308. doi: 10.1016/0049-0172(81)90006-8. [DOI] [PubMed] [Google Scholar]
  10. Brown E. A., Macgregor G. A., Maini R. N. Failure of captopril to reverse the renal crisis of scleroderma. Ann Rheum Dis. 1983 Feb;42(1):52–53. doi: 10.1136/ard.42.1.52. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Capodicasa G., De Santo N. G., Galione A., Vinti V., Giannetto V., Annaloro R., Vaccaro F., Bellavia C., Picone F., Riccobene G. Clinical effectiveness of apheresis in the treatment of progressive systemic sclerosis. Int J Artif Organs. 1983 Jul;6 (Suppl 1):81–86. [PubMed] [Google Scholar]
  12. Casas J. A., Saway P. A., Villarreal I., Nolte C., Menajovsky B. L., Escudero E. E., Blackburn W. D., Alarcón G. S., Subauste C. P. 5-fluorouracil in the treatment of scleroderma: a randomised, double blind, placebo controlled international collaborative study. Ann Rheum Dis. 1990 Nov;49(11):926–928. doi: 10.1136/ard.49.11.926. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. D'Angelo G., Stern H. S., Myers E. Rectal prolapse in scleroderma: case report and review of the colonic complications of scleroderma. Can J Surg. 1985 Jan;28(1):62–63. [PubMed] [Google Scholar]
  14. Dodman B., Rowell N. R. Low molecular weight dextran in systemic sclerosis and Raynaud's phenomenon. Acta Derm Venereol. 1982;62(5):440–442. [PubMed] [Google Scholar]
  15. Ehrlich H. P., Bornstein P. Microtubules in transcellular movement of procollagen. Nat New Biol. 1972 Aug 30;238(87):257–260. doi: 10.1038/newbio238257a0. [DOI] [PubMed] [Google Scholar]
  16. Fenaux P., Merignargues S., Pagniez D., Janin A., Lucidarme D., Bauters F. Cutaneous sclerosis, aplastic anemia, and antithymocyte globulin. Ann Intern Med. 1989 Apr 1;110(7):575–576. doi: 10.7326/0003-4819-110-7-575_2. [DOI] [PubMed] [Google Scholar]
  17. Franks A. G., Jr Topical glyceryl trinitrate as adjunctive treatment in Raynaud's disease. Lancet. 1982 Jan 9;1(8263):76–77. doi: 10.1016/s0140-6736(82)90215-x. [DOI] [PubMed] [Google Scholar]
  18. Fries J. F., Wasner C., Brown J., Feigenbaum P. A controlled trial of antihypertensive therapy in systemic sclerosis (scleroderma). Ann Rheum Dis. 1984 Jun;43(3):407–410. doi: 10.1136/ard.43.3.407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Fuchs D., Fruchter L., Fishel B., Holtzman M., Yaron M. Colchicine suppression of local inflammation due to calcinosis in dermatomyositis and progressive systemic sclerosis. Clin Rheumatol. 1986 Dec;5(4):527–530. [PubMed] [Google Scholar]
  20. Furst D. E., Clements P. J., Harris R., Ross M., Levy J., Paulus H. E. Measurement of clinical change in progressive systemic sclerosis: a 1 year double-blind placebo-controlled trial of N-acetylcysteine. Ann Rheum Dis. 1979 Aug;38(4):356–361. doi: 10.1136/ard.38.4.356. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Furst D. E., Clements P. J., Hillis S., Lachenbruch P. A., Miller B. L., Sterz M. G., Paulus H. E. Immunosuppression with chlorambucil, versus placebo, for scleroderma. Results of a three-year, parallel, randomized, double-blind study. Arthritis Rheum. 1989 May;32(5):584–593. doi: 10.1002/anr.1780320512. [DOI] [PubMed] [Google Scholar]
  22. Guillevin L., Chouvet B., Mery C., De Gery A., Thivolet J., Godeau P., Delbarre F. Treatment of progressive systemic sclerosis using factor XIII. Pharmatherapeutica. 1985;4(2):76–80. [PubMed] [Google Scholar]
  23. Guillevin L., Leon A., Levy Y., Bletry O., Gayraud M., Andreu G., Godeau P. Treatment of progressive systemic sclerosis with plasma exchange. Seven cases. Int J Artif Organs. 1983 Nov;6(6):315–318. [PubMed] [Google Scholar]
  24. Guttadauria M., Diamond H., Kaplan D. Colchicine in the treatment of scleroderma. J Rheumatol. 1977 Autumn;4(3):272–276. [PubMed] [Google Scholar]
  25. Harris E. D., Jr, Krane S. M. Effects of colchicine on collagenase in cultures of rheumatoid synovium. Arthritis Rheum. 1971 Nov-Dec;14(6):669–684. doi: 10.1002/art.1780140602. [DOI] [PubMed] [Google Scholar]
  26. Helfrich D. J., Banner B., Steen V. D., Medsger T. A., Jr Normotensive renal failure in systemic sclerosis. Arthritis Rheum. 1989 Sep;32(9):1128–1134. doi: 10.1002/anr.1780320911. [DOI] [PubMed] [Google Scholar]
  27. Horowitz M., Maddern G. J., Maddox A., Wishart J., Chatterton B. E., Shearman D. J. Effects of cisapride on gastric and esophageal emptying in progressive systemic sclerosis. Gastroenterology. 1987 Aug;93(2):311–315. doi: 10.1016/0016-5085(87)91020-1. [DOI] [PubMed] [Google Scholar]
  28. Ingram D. G., Cho H. J. Aleutian disease in mink: virology, immunology and pathogenesis. J Rheumatol. 1974 Mar;1(1):74–92. [PubMed] [Google Scholar]
  29. Jansen G. T., Barraza D. F., Ballard J. L., Honeycutt W. M., Dillaha C. J. Generalized scleroderma. Treatment with an immunosuppressive agent. Arch Dermatol. 1968 Jun;97(6):690–698. doi: 10.1001/archderm.97.6.690. [DOI] [PubMed] [Google Scholar]
  30. Jayson M. I., Lovell C., Black C. M., Wilson R. S. Penicillamine therapy in systemic sclerosis. Proc R Soc Med. 1977;70 (Suppl 3):82–88. doi: 10.1177/00359157770700S327. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Jean F., Aubert A., Bloch F., Petite J. P., Priollet P., Fiessinger J. N., Husson J. M., Billaud E. Effects of diltiazem versus nifedipine on lower esophageal sphincter pressure in patients with progressive systemic sclerosis. Arthritis Rheum. 1986 Aug;29(8):1054–1055. doi: 10.1002/art.1780290821. [DOI] [PubMed] [Google Scholar]
  32. Jiménez S. A. Cellular immune dysfunction and the pathogenesis of scleroderma. Semin Arthritis Rheum. 1983 Aug;13(1 Suppl 1):104–113. doi: 10.1016/0049-0172(83)90029-x. [DOI] [PubMed] [Google Scholar]
  33. Jones N. F., Imbriglia J. E., Steen V. D., Medsger T. A. Surgery for scleroderma of the hand. J Hand Surg Am. 1987 May;12(3):391–400. doi: 10.1016/s0363-5023(87)80012-6. [DOI] [PubMed] [Google Scholar]
  34. Jones N. F., Raynor S. C., Medsger T. A. Microsurgical revascularisation of the hand in scleroderma. Br J Plast Surg. 1987 May;40(3):264–269. doi: 10.1016/0007-1226(87)90120-2. [DOI] [PubMed] [Google Scholar]
  35. Kahaleh M. B., Sherer G. K., LeRoy E. C. Endothelial injury in scleroderma. J Exp Med. 1979 Jun 1;149(6):1326–1335. doi: 10.1084/jem.149.6.1326. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Kahan A., Amor B., Menkes C. J., Strauch G. Recombinant interferon-gamma in the treatment of systemic sclerosis. Am J Med. 1989 Sep;87(3):273–277. doi: 10.1016/s0002-9343(89)80150-0. [DOI] [PubMed] [Google Scholar]
  37. Kahan A., Bour B., Couturier D., Amor B., Menkes C. J. Nifedipine and esophageal dysfunction in progressive systemic sclerosis. A controlled manometric study. Arthritis Rheum. 1985 May;28(5):490–495. doi: 10.1002/art.1780280504. [DOI] [PubMed] [Google Scholar]
  38. Kahan A., Devaux J. Y., Amor B., Menkès C. J., Weber S., Nitenberg A., Venot A., Guérin F., Degeorges M., Roucayrol J. C. Nifedipine and thallium-201 myocardial perfusion in progressive systemic sclerosis. N Engl J Med. 1986 May 29;314(22):1397–1402. doi: 10.1056/NEJM198605293142201. [DOI] [PubMed] [Google Scholar]
  39. Kallenberg C. G., Jansen H. M., Elema J. D., The T. H. Steroid-responsive interstitial pulmonary disease in systemic sclerosis. Monitoring by bronchoalveolar lavage. Chest. 1984 Sep;86(3):489–492. doi: 10.1378/chest.86.3.489. [DOI] [PubMed] [Google Scholar]
  40. Keller J., Kaltenecker A., Schricker K. T., Neidhardt B., Hornstein O. P. Inhibition of platelet aggregation by a new stable prostacyclin introduced in therapy of patients with progressive scleroderma. Arch Dermatol Res. 1985;277(4):323–325. doi: 10.1007/BF00509089. [DOI] [PubMed] [Google Scholar]
  41. LeRoy E. C., Fleischmann R. M. The management of renal scleroderma: experience with dialysis, nephrectomy and transplantation. Am J Med. 1978 Jun;64(6):974–978. doi: 10.1016/0002-9343(78)90452-7. [DOI] [PubMed] [Google Scholar]
  42. Lian J. B., Skinner M., Glimcher M. J., Gallop P. The presence of gamma-carboxyglutamic acid in the proteins associated with ectopic calcification. Biochem Biophys Res Commun. 1976 Nov 22;73(2):349–355. doi: 10.1016/0006-291x(76)90714-2. [DOI] [PubMed] [Google Scholar]
  43. Maekawa Y., Nogita T., Yamada M. Favorable effects of plasma factor XIII on lower esophageal sphincter pressure of progressive systemic sclerosis. Arch Dermatol. 1987 Nov;123(11):1440–1441. [PubMed] [Google Scholar]
  44. McFadyen I. J., Housley E., MacPherson A. I. Intraarterial reserpine administration in Raynaud syndrome. Arch Intern Med. 1973 Oct;132(4):526–528. [PubMed] [Google Scholar]
  45. Medsger T. A., Jr Progressive systemic sclerosis. Clin Rheum Dis. 1983 Dec;9(3):655–670. [PubMed] [Google Scholar]
  46. Medsger T. A., Jr Treatment of systemic sclerosis. Rheum Dis Clin North Am. 1989 Aug;15(3):513–531. [PubMed] [Google Scholar]
  47. Mizushima Y., Shiokawa Y., Homma M., Kashiwazaki S., Ichikawa Y., Hashimoto H., Sakuma A. A multicenter double blind controlled study of lipo-PGE1, PGE1 incorporated in lipid microspheres, in peripheral vascular disease secondary to connective tissue disorders. J Rheumatol. 1987 Feb;14(1):97–101. [PubMed] [Google Scholar]
  48. Naylor W. P., Manor R. C. Fabrication of a flexible prosthesis for the edentulous scleroderma patient with microstomia. J Prosthet Dent. 1983 Oct;50(4):536–538. doi: 10.1016/0022-3913(83)90577-2. [DOI] [PubMed] [Google Scholar]
  49. Naylor W. P. Oral management of the scleroderma patient. J Am Dent Assoc. 1982 Nov;105(5):814–817. doi: 10.14219/jada.archive.1982.0466. [DOI] [PubMed] [Google Scholar]
  50. Netscher D. T., Richardson J. D. Complications requiring operative intervention in scleroderma. Surg Gynecol Obstet. 1984 May;158(5):507–512. [PubMed] [Google Scholar]
  51. Nimni M. E. A defect in the intramolecular and intermolecular cross-linking of collagen caused by penicillamine. I. Metabolic and functional abnormalities in soft tissues. J Biol Chem. 1968 Apr 10;243(7):1457–1466. [PubMed] [Google Scholar]
  52. Norris R. W., Brown H. G. The proximal interphalangeal joint in systemic sclerosis and its surgical management. Br J Plast Surg. 1985 Oct;38(4):526–531. doi: 10.1016/0007-1226(85)90015-3. [DOI] [PubMed] [Google Scholar]
  53. Orringer M. B., Orringer J. S., Dabich L., Zarafonetis C. J. Combined Collis gastroplasty--fundoplication operations for scleroderma reflux esophagitis. Surgery. 1981 Oct;90(4):624–630. [PubMed] [Google Scholar]
  54. Ramirez-Mata M., Ibañez G., Alarcon-Segovia D. Stimulatory effect of metoclopramide on the esophagus and lower esophageal sphincter of patients of patients with PSS. Arthritis Rheum. 1977 Jan-Feb;20(1):30–34. doi: 10.1002/art.1780200105. [DOI] [PubMed] [Google Scholar]
  55. Rees W. D., Leigh R. J., Christofides N. D., Bloom S. R., Turnberg L. A. Interdigestive motor activity in patients with systemic sclerosis. Gastroenterology. 1982 Sep;83(3):575–580. [PubMed] [Google Scholar]
  56. Rosenbloom J., Feldman G., Freundlich B., Jimenez S. A. Inhibition of excessive scleroderma fibroblast collagen production by recombinant gamma-interferon. Association with a coordinate decrease in types I and III procollagen messenger RNA levels. Arthritis Rheum. 1986 Jul;29(7):851–856. doi: 10.1002/art.1780290706. [DOI] [PubMed] [Google Scholar]
  57. Scherbel A. L. The effect of percutaneous dimethyl sulfoxide on cutaneous manifestations of systemic sclerosis. Ann N Y Acad Sci. 1983;411:120–130. doi: 10.1111/j.1749-6632.1983.tb47293.x. [DOI] [PubMed] [Google Scholar]
  58. Seeger M. W., Furst D. E. Effects of splinting in the treatment of hand contractures in progressive systemic sclerosis. Am J Occup Ther. 1987 Feb;41(2):118–121. doi: 10.5014/ajot.41.2.118. [DOI] [PubMed] [Google Scholar]
  59. Seibold J. R., Jageneau A. H. Treatment of Raynaud's phenomenon with ketanserin, a selective antagonist of the serotonin2 (5-HT2) receptor. Arthritis Rheum. 1984 Feb;27(2):139–146. doi: 10.1002/art.1780270204. [DOI] [PubMed] [Google Scholar]
  60. Smith C. D., McKendry R. J. Controlled trial of nifedipine in the treatment of Raynaud's phenomenon. Lancet. 1982 Dec 11;2(8311):1299–1301. doi: 10.1016/s0140-6736(82)91508-2. [DOI] [PubMed] [Google Scholar]
  61. Stafford-Brady F. J., Kahn H. J., Ross T. M., Russell M. L. Advanced scleroderma bowel: complications and management. J Rheumatol. 1988;15(5):869–874. [PubMed] [Google Scholar]
  62. Steen V. D., Blair S., Medsger T. A., Jr The toxicity of D-penicillamine in systemic sclerosis. Ann Intern Med. 1986 May;104(5):699–705. doi: 10.7326/0003-4819-104-5-699. [DOI] [PubMed] [Google Scholar]
  63. Steen V. D., Costantino J. P., Shapiro A. P., Medsger T. A., Jr Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med. 1990 Sep 1;113(5):352–357. doi: 10.7326/0003-4819-113-5-352. [DOI] [PubMed] [Google Scholar]
  64. Steen V. D., Medsger T. A., Jr, Osial T. A., Jr, Ziegler G. L., Shapiro A. P., Rodnan G. P. Factors predicting development of renal involvement in progressive systemic sclerosis. Am J Med. 1984 May;76(5):779–786. doi: 10.1016/0002-9343(84)90986-0. [DOI] [PubMed] [Google Scholar]
  65. Steen V. D., Medsger T. A., Jr, Rodnan G. P. D-Penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis. Ann Intern Med. 1982 Nov;97(5):652–659. doi: 10.7326/0003-4819-97-5-652. [DOI] [PubMed] [Google Scholar]
  66. Steen V. D., Owens G. R., Redmond C., Rodnan G. P., Medsger T. A., Jr The effect of D-penicillamine on pulmonary findings in systemic sclerosis. Arthritis Rheum. 1985 Aug;28(8):882–888. doi: 10.1002/art.1780280807. [DOI] [PubMed] [Google Scholar]
  67. Steen V. D., Powell D. L., Medsger T. A., Jr Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum. 1988 Feb;31(2):196–203. doi: 10.1002/art.1780310207. [DOI] [PubMed] [Google Scholar]
  68. Surwit R. S., Gilgor R. S., Allen L. M., Duvic M. A double-blind study of prazosin in the treatment of Raynaud's phenomenon in scleroderma. Arch Dermatol. 1984 Mar;120(3):329–331. [PubMed] [Google Scholar]
  69. Talal N. The goals of immunologic intervention in autoimmune disease. J Autoimmun. 1989 Jun;2 (Suppl):257–264. doi: 10.1016/0896-8411(89)90138-8. [DOI] [PubMed] [Google Scholar]
  70. Torres M. A., Furst D. E. Treatment of generalized systemic sclerosis. Rheum Dis Clin North Am. 1990 Feb;16(1):217–241. [PubMed] [Google Scholar]
  71. Traub Y. M., Shapiro A. P., Rodnan G. P., Medsger T. A., McDonald R. H., Jr, Steen V. D., Osial T. A., Jr, Tolchin S. F. Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis. Review of a 25-year experience with 68 cases. Medicine (Baltimore) 1983 Nov;62(6):335–352. doi: 10.1097/00005792-198311000-00001. [DOI] [PubMed] [Google Scholar]
  72. Waeber B., Schaller M. D., Wauters J. P., Brunner H. R. Deterioration of renal function in hypertensive patients with scleroderma despite blood pressure normalization with captopril. Klin Wochenschr. 1984 Aug 1;62(15):728–730. doi: 10.1007/BF01725706. [DOI] [PubMed] [Google Scholar]
  73. Wollheim F. A., Akesson A. Treatment of systemic sclerosis in 1988. Semin Arthritis Rheum. 1989 Feb;18(3):181–188. doi: 10.1016/0049-0172(89)90060-7. [DOI] [PubMed] [Google Scholar]
  74. Yocum D. E., Hodes R., Sundstrom W. R., Cleeland C. S. Use of biofeedback training in treatment of Raynaud's disease and phenomenon. J Rheumatol. 1985 Feb;12(1):90–93. [PubMed] [Google Scholar]
  75. Zachariae H., Zachariae E. Cyclosporin A in systemic sclerosis. Br J Dermatol. 1987 May;116(5):741–742. doi: 10.1111/j.1365-2133.1987.tb05912.x. [DOI] [PubMed] [Google Scholar]
  76. al-Sabbagh M. R., Steen V. D., Zee B. C., Nalesnik M., Trostle D. C., Bedetti C. D., Medsger T. A., Jr Pulmonary arterial histology and morphometry in systemic sclerosis: a case-control autopsy study. J Rheumatol. 1989 Aug;16(8):1038–1042. [PubMed] [Google Scholar]
  77. de Clerck L. S., Dequeker J., Francx L., Demedts M. D-penicillamine therapy and interstitial lung disease in scleroderma. A long-term followup study. Arthritis Rheum. 1987 Jun;30(6):643–650. doi: 10.1002/art.1780300607. [DOI] [PubMed] [Google Scholar]
  78. van den Hoogen F. H., Boerbooms A. M., van de Putte L. B. Methotrexate treatment in scleroderma. Am J Med. 1989 Jul;87(1):116–117. doi: 10.1016/s0002-9343(89)80499-1. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES